MedTrace Logo

Neoadjuvant Imatinib in Dermatofibrosarcoma Protuberans

NCT00243191 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2012-03-29

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to examine the effect of imatinib on dermatofibrosarcoma protuberan tumors.

Conditions

  • Dermatofibrosarcoma Protuberans

Interventions

DRUG

imatinib mesylate

400 mg orally twice a day for 10 - 14 days

Sponsors & Collaborators

  • Sarcoma Alliance for Research through Collaboration

    lead OTHER

Principal Investigators

  • Scott Schuetze, MD, PhD · University of Michigan

Study Design

Allocation
NON_RANDOMIZED
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-05-31
Primary Completion
2009-09-30
Completion
2009-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00243191 on ClinicalTrials.gov